Business Context and Reporting Period
This Form 8-K filing by RXi Pharmaceuticals Corporation (referred to as Phio Pharmaceuticals Corp. in metadata) covers the date of April 18, 2013. The report details corporate governance changes, specifically the appointment of new directors to the Board of Directors effective as of the report date.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and board appointments.
Material Changes
The primary material change reported is the appointment of H. Paul Dorman and Curtis A. Lockshin, Ph.D., to the Board of Directors. Their terms are set to last until the 2013 annual meeting of stockholders. The Board has not yet assigned them to specific committees.
Compensation and Management Commentary
The Company entered into agreements with the new directors outlining the following compensation structure:
- Annual Retainer: $20,000 per director, payable in quarterly installments of $5,000.
- Initial Option Grant: A one-time grant in the first year of service for up to 1,000,000 shares of common stock, vesting quarterly over one year under the 2012 Incentive Plan.
- Subsequent Option Grants: An annual grant in each subsequent year for up to 500,000 shares of common stock, vesting quarterly over one year.
- Expenses: Reimbursement for travel and reasonable out-of-pocket expenses.
The filing contains no guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure of these appointments.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 1,000,000 share option grants for Mr. Dorman and Dr. Lockshin.
- Confirm the total number of shares reserved under the 2012 Incentive Plan to assess potential dilution.
- Review the 2013 annual meeting proxy statement for the final committee assignments of the new directors.
- Check subsequent filings for any changes to the compensation agreements or the directors' tenure.